These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35283984)

  • 1. Immunization against severe acute respiratory syndrome Coronavirus 2: an overview.
    El-Masry EA
    Afr Health Sci; 2021 Dec; 21(4):1574-1583. PubMed ID: 35283984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
    Iftikhar A; Jabeen F; Manzoor M; Younis T; Shaheen M
    Acta Microbiol Immunol Hung; 2020 Jul; 67(2):87-90. PubMed ID: 32619190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
    Demers-Mathieu V; DaPra C; Medo E
    Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
    Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
    Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.
    Saied AA; Nascimento MSL; do Nascimento Rangel AH; Skowron K; Grudlewska-Buda K; Dhama K; Shah J; Abdeen A; El-Mayet FS; Ahmed H; Metwally AA
    J Med Virol; 2022 Oct; 94(10):4599-4610. PubMed ID: 35655326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
    Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
    Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
    Ranganathan S; Iyer RN
    Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.
    Sullivan HC; Roback JD
    Transfus Med Rev; 2020 Jul; 34(3):145-150. PubMed ID: 32359788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.
    Tharmalingam T; Han X; Wozniak A; Saward L
    Hum Vaccin Immunother; 2022 Apr; 18(2):1886560. PubMed ID: 34010089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
    Uriu K; Cárdenas P; Muñoz E; Barragan V; Kosugi Y; Shirakawa K; Takaori-Kondo A; ; Sato K
    J Infect Dis; 2022 Sep; 226(7):1200-1203. PubMed ID: 35176774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 18. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31.
    Levi-Schaffer F; de Marco A
    Br J Pharmacol; 2021 Sep; 178(17):3359-3372. PubMed ID: 33401333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.
    Iqbal Yatoo M; Hamid Z; Rather I; Nazir QUA; Bhat RA; Ul Haq A; Magray SN; Haq Z; Sah R; Tiwari R; Natesan S; Bilal M; Harapan H; Dhama K
    Hum Vaccin Immunother; 2021 Jul; 17(7):1897-1909. PubMed ID: 33577374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.